CLINICAL USE


Nucleoside reverse transcriptase inhibitor:Treatment of HIV in combination with other antiretroviral drugs

DOSE IN NORMAL RENAL FUNCTION

60 kg: 40 mg twice daily

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :224.2
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :<1
  • %Excreted unchanged in urine &nbsp &nbsp : 40

  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :0.5

  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :1–1.5/5.5–8

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

    26–50 60 kg: 20 mg twice daily<25 60 kg: 20 mg daily

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR<25 mL/min

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in GFR<25 mL/min
  • HDF/high flux &nbsp :Dialysed. Dose as in GFR<25 mL/min
  • CAV/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR=26–50 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • Antivirals: zidovudine may inhibit intracellular activation – avoid concomitant use; increased risk of side effects with didanosine; effects possibly inhibited by ribavirinCytotoxics: effects possibly inhibited by doxorubicin; increased risk of toxicity with hydroxycarbamide – avoid concomitant use

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    Administer at least an hour before food

    OTHER INFORMATION

    Clearance by haemodialysis is 120 mL/min Lactic acidosis, sometimes fatal, has been reported with the use of nucleoside analoguesPatients with ERF are more likely to develop peripheral neuropathy.
    Tags:

    • Related News

    sorafenib.txt

    tazocin.txt